Burning Rock Dx(US:BNR) Jin Rong Jie·2025-07-08 14:27Core Insights - The stock price of Burning Stone Medical (BNR) increased by 2.81% to $3.66 per share, with a total market capitalization of approximately $39.41 million as of July 8 [1] - For the fiscal year ending March 31, 2025, the company reported total revenue of 133 million RMB, reflecting a year-on-year growth of 5.94%, while the net profit attributable to shareholders was -13.5 million RMB, showing a significant year-on-year improvement of 88.89% [1] - Burning Stone Medical is set to release its mid-year report for the fiscal year 2025 on August 28, with the actual disclosure date subject to company announcements [1] Company Overview - Founded in 2014, Burning Stone Medical focuses on providing clinically valuable next-generation sequencing (NGS) for precision oncology, with a mission to "guard the light of life with science" [1] - The company's business and research directions include: 1) detection for cancer patients, holding a leading market share in China; 2) collaborations with global anti-cancer pharmaceutical companies for biomarkers and companion diagnostics; 3) early detection of multiple cancer types [1] Regulatory Milestones - In July 2018, Burning Stone Medical received the first NGS testing kit certification for tumors from the National Medical Products Administration (NMPA) in China, marking a significant milestone in the in vitro diagnostic field [2] - The laboratory in Guangzhou has passed the technical review by the Guangdong Provincial Clinical Testing Center and has obtained quality system certifications from CLIA and CAP in the United States [2] - The laboratory located in California has also received CLIA and CAP certifications, indicating the company's commitment to developing innovative and reliable NGS testing products to advance the field of precision oncology [2]